NewAmsterdam Pharma details COO Kling's exit: unvested equity canceled, $50k/mo advisor fee

NewAmsterdam Pharma Co N.V.

Douglas Kling resigned as COO effective Aug 14, 2026, to become CEO of another clinical-stage biotech.
Unvested stock options and RSUs canceled as of separation date, except those vesting on continued service through May 14, 2027.
Kling entered Advisor Agreement with NewAmsterdam Pharma B.V. for $50,000/month plus expenses for PREVAIL trial and other clinical programs.
Advisor Agreement runs to May 14, 2027; includes confidentiality, non-disparagement, non-solicitation covenants.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.